Nasopharyngeal Cancer Market Outlook 2031:
The global nasopharyngeal cancer market size was valued at USD XX Billion in 2022 and is projected to reach USD XX Billion by 2031, expanding at a CAGR of 2.7% during the forecast period 2023 - 2031. The growth of the market is attributed to the Growing cases of cancer, increasing geriatric population, and advancements in medical technologies for diagnostic and prevention of cancers.
Nasopharyngeal cancer is a type of head and neck cancer which originates from upper part of the throat and behind nose and near the base of the skull know as nasopharynx. Cancer is a disease when some of the body’s cells grow uncontrollably and spread to other parts of the body. Nasopharynx is the upper part of the throat that lies behind the nose, it is a box-like chamber and lies just above the soft part of the rood of the mouth and just behind the nasal passages. It is diagnosed as a chronic disorder.
Generally nasopharyngeal cancers are mostly nasopharyngeal carcinoma (NPC) which is by far the most common cancer in the nasopharynx. Carcinoma is cancer that originates from the cells that line the internal and external surfaces of the body called epithelial cells. Treatment begins with diagnosis of the cancer with tests and procedures such as physical exam and patient history, neurological exam, biopsy, upper endoscopy, MRI (magnetic resonance imaging), and CT scan, among others.
Nasopharyngeal Cancer Market Trends, Drivers, Restraints, and Opportunities
- Increasing cases of cancers among the population worldwide due to growth in tobacco and alcohol consumption is anticipated to push the nasopharyngeal cancer market expansion in the coming years.
- Rising burden of disease, growing awareness towards diagnosis and treatment, and rapid adoption of modern healthcare medical devices are major factors spurring the nasopharyngeal cancer market growth during the forecast period.
- High price treatment and therapeutic procedures such as diagnosis, surgeries, chemotherapy, and radiation therapy are expected to hamper the nasopharyngeal cancer market expansion.
- Lack of medical insurance among majority of population in developing and underdeveloped regions across the globe and high prices of drugs adding financial burden of the treatment are some of the major challenges that hinder the nasopharyngeal cancer market growth in the coming years.
- R&D investment and technological advancements in healthcare devices particularly in diagnostic and prevention are anticipated to offer significant opportunities for the market players.
Scope of Nasopharyngeal Cancer Market Report
The report on the global nasopharyngeal cancer market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Nasopharyngeal Cancer Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Types (Non-keratinizing undifferentiated carcinoma, Non-keratinizing differentiated carcinoma, Keratinizing squamous cell carcinoma), Therapies (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), End Users (Hospitals, Clinics, Cancer Treatment & Rehabilitation Centers, Ambulatory Surgery Centers, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Biocon Limited, Bristol Myers Squibb,Eli Lilly and Company, Cyclacel Pharmaceuticals, Sanofi S.A., Celgene Corporation, BioDiem Ltd, Merck & Co., Inc.
Nasopharyngeal Cancer Market Segment Insights
Non-Keratinizing undifferentiated carcinoma segment is projected to account for a major market share
Based on types, the nasopharyngeal cancer market share divided into non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, keratinizing squamous cell carcinoma. Non-Keratinizing undifferentiated carcinoma segment is projected to account for a major market share. It is the most common type of NPC among the three, they also tend to respond better to treatment depending upon the stage of cancer or how far it is spread.
Radiation therapy segment is expected to represent significant market share
Based on therapies, the nasopharyngeal cancer market share is segmented into chemotherapy, immunotherapy, radiation therapy, and others. Radiation therapy segment is expected to represent significant market share. The treatment procedure is at an early clinical phase with positive outlook estimated due to which commercial applications on a large scale is projected during the end of forecast period. In this treatment procedure, a person receives radiation therapy followed by use of drugs to destroy the cancer cells.
On the other hand, chemotherapy is projected to grow at a considerable rate during the forecast period. The segment growth is attributed to the recent success in adoption of radiation and chemotherapy at the same time. Chemotherapy makes cancer cells more sensitive to radiation therapy, aiding in destroying more of the tumor, it also helps eradicate cancer that may have spread that may spread to other parts of the body.
Hospital segment is anticipated to exhibit a robust CAGR
In terms of end users, the nasopharyngeal cancer market is segregated into hospitals, clinics, cancer treatment & rehabilitation centers, ambulatory surgery centers, and others. Hospital segment is anticipated to exhibit a robust CAGR due to rapid adoption of modern cancer diagnostic and prevention technologies, increasing medical expenditure in the emerging markets, and growing healthcare awareness.
North America is expected to dominate the market
On the basis of regions, the nasopharyngeal cancer market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing research and development activities by key market players in the region to develop better treatment procedures.
However, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing cases of cancers in the head and neck areas. Market players are investing heavily in the developing economies across the regions which is expected to drive the market expansion during the forecast period.
- Non-keratinizing undifferentiated carcinoma
- Non-keratinizing differentiated carcinoma
- Keratinizing squamous cell carcinoma
- Radiation Therapy
- Cancer Treatment & Rehabilitation Centers
- Ambulatory Surgery Centers
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Key players competing in the nasopharyngeal cancer market include Biocon Limited, Bristol Myers Squibb,Eli Lilly and Company, Cyclacel Pharmaceuticals, Sanofi S.A., Celgene Corporation, BioDiem Ltd, Merck & Co., Inc.